Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart for Moderate to Severe Hidradenitis Suppurativa (Phase 2b)
2024-520039-33-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Tulisokibart with Placebo (2 arms). Primary endpoint: HiSCR50 at Week 16. Planned start Aug 2025; status: authorised.
02
Drugs
tulisokibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-520039-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520039-33-00.